Valuation: Vivos Inc.

Market Cap 20.02M 18.17M 16.79M 15.14M 28.59M 1.87B 29.68M 202M 80M 1.01B 75.1M 73.52M 3.19B P/E 2024
-16.2x
P/E 2025 -10.2x
Enterprise Value 18.57M 16.86M 15.57M 14.05M 26.53M 1.74B 27.54M 188M 74.23M 936M 69.68M 68.21M 2.96B EV / Sales 2024
1,724x
EV / Sales 2025 438x
Free-Float
96.65%
Yield 2024 *
-
Yield 2025 -
1 day-3.75%
1 week+37.85%
Current month+31.70%
1 month+20.41%
3 months+7.27%
6 months-12.98%
Current year-14.37%
1 week 0.04
Extreme 0.0405
0.06
1 month 0.04
Extreme 0.04
0.06
Current year 0.04
Extreme 0.0391
0.12
1 year 0.04
Extreme 0.0391
0.12
3 years 0.04
Extreme 0.0391
0.26
5 years 0.04
Extreme 0.0391
0.26
10 years 0.01
Extreme 0.0065
1.92
Manager TitleAgeSince
Chief Executive Officer 79 13/12/2016
President 44 14/09/2025
Director of Finance/CFO 59 30/11/2018
Director TitleAgeSince
Chairman 81 13/12/2016
Director/Board Member 79 01/08/2017
Date Insider Type Main position Quantity % Market Cap. Importance
07/10/26 Issuer sale

Chairman

-385,302 100.0000%
30/09/26 Buy

Chief Executive Officer

200,000 0.0405%
16/09/26 Buy

Chairperson

25,550 0.0052%
Change 5-day change 1-year change 3-year change Capi.($)
-3.75%+37.85%-24.36%+14.56% 20.02M
-0.51%-4.17%+21.35%+47.56% 256B
-1.78%-4.37%+2.43%+8.67% 162B
-1.34%-3.92%-20.91%+41.63% 152B
-1.16%-3.55%-57.63%-20.66% 63.33B
-1.35%+2.07%+25.28%+58.68% 61.59B
-1.59%+0.84%+3.64%-13.47% 53.86B
-0.41%-3.31%+19.01%+52.01% 48.75B
-3.62%-5.07%+4.71%+64.30% 48.46B
-0.87%-5.42%+18.99%+71.74% 44.56B
Average -1.70%-0.26%-0.75%+32.50% 89B
Weighted average by Cap. -1.30%-0.31%+3.14%+34.07%

Financials

2024 2025
Net sales 28K 25.41K 23.48K 21.18K 39.98K 2.62M 41.51K 283K 112K 1.41M 105K 103K 4.46M 68.38K 62.07K 57.34K 51.73K 97.66K 6.39M 101K 691K 273K 3.45M 257K 251K 10.89M
Net income -2.91M -2.64M -2.44M -2.2M -4.16M -272M -4.32M -29.41M -11.63M -147M -10.92M -10.69M -464M -3.07M -2.78M -2.57M -2.32M -4.38M -286M -4.55M -30.98M -12.25M -155M -11.5M -11.26M -488M
Net Debt -2.21M -2.01M -1.86M -1.67M -3.16M -207M -3.28M -22.36M -8.84M -112M -8.3M -8.13M -352M -1.44M -1.31M -1.21M -1.09M -2.06M -135M -2.14M -14.59M -5.77M -72.81M -5.42M -5.3M -230M
Projected Income Statement - Annual - Vivos Inc.
Logo Vivos Inc.
Vivos Inc. is a radiation oncology medical device company. The Company has developed an Yttrium-90-based injectable Precision Radionuclide Therapy medical device to treat tumors in animals (IsoPet) and humans (RadioGel). Using the Company’s proprietary hydrogel technology, PRnT uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers. University veterinary hospitals use the IsoPet Solutions division to demonstrate animal cancers’ safety and therapeutic effectiveness. RadioGel is a hydrogel liquid containing tiny yttrium-90 phosphate microparticles that may be administered directly into a tumor.
Employees
1
Date Price Change Volume
16/11/26 US$0.0405 -7.95% 1,702,647
13/11/26 US$0.0440 -.--% 248,482
12/11/26 US$0.0440 -0.16% 385,041
11/11/26 US$0.0441 -1.41% 159,097
10/11/26 US$0.0447 +4.44% 84,085
  1. Stock Market
  2. Stocks
  3. RDGL Stock